Clinical trials recruiting for Small cell lung cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
  NCT07557225 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
  NCT07508852 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
  NCT07175077 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
  NCT07026669 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter Cancer Biospecimen Collection Study
  NCT04510129 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
  NCT06592638 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07373964 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07005128 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 164 locations
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
  NCT07010263 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
  NCT06095505 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of Armored CAR T Cells in People With Cancer
  NCT07783477 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
  NCT05924841 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
  NCT06505824 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
  NCT06873555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of DXC014 in Patients With Advanced Solid Tumors.
  NCT07177937 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of Hospital-at-Home for People Receiving Tarlatamab
  NCT06957314 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
  NCT07174583 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
  NCT06970795 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
  NCT07208773 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
  NCT07218146 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 155 locations
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
  NCT06805825 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
  NCT07365241 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 63 locations
• A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
  NCT06780137 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
  NCT06498479 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
  NCT06480864 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
  NCT06160596 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
  NCT06771518 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
  NCT07625644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
  NCT06255197 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
  NCT06514118 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female) · 3 locations
• Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
  NCT02622581 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
  NCT03093688 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · 36 locations
• DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
  NCT07545954 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
  NCT06283719 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
  NCT04952480 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
  NCT05068232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 117 locations
• Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
  NCT06717243 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 2 locations
• Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
  NCT06527898 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
  NCT06840704 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
  NCT04951947 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
  NCT06103682 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
  NCT05903092 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Molecular Analysis and Treatment Options of SCLC
  NCT05945745 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
  NCT04539977 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
  NCT04199741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
  NCT05797493 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
  NCT06922539 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
  NCT05363280 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase 2 Study of Fingolimod in Lung Cancers
  NCT06424067 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
  NCT07778316 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
  NCT07424547 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma
  NCT03467360 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
  NCT06769971 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
  NCT05552846 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
  NCT04342429 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SKB500 Combinations in Patients With Small Cell Lung Cancer
  NCT07296809 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
  NCT06457906 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Serplulimab Combined With CCRT for LS-SCLC.
  NCT06295926 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
  NCT07155200 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
  NCT07189455 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of GV20-0251 in Participants With Solid Tumor Malignancies
  NCT07070518 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
  NCT06613009 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
  NCT06931626 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
  NCT05450965 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
  NCT07531095 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 27 locations
• Study of Trilaciclib and Lurbinectidin
  NCT05578326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
  NCT07231445 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
  NCT05978284 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
  NCT06467786 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
  NCT07803848 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
  NCT07476287 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
  NCT05628376 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Talazoparib and Thoracic RT for ES-SCLC
  NCT04170946 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tarlatamab for SCLC Brain Metastases
  NCT07402343 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Tempus Small Cell Lung Cancer Observational Study (Sculptor)
  NCT05257551 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
  NCT07583511 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
  NCT02146170 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Small cell lung cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Small cell lung cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.